Explore whether heavy objects really fall faster than light ones. CBP-fired military laser triggered El Paso communication meltdown Gabbard whistleblower complaint based on intercepted conversation ...

Abstract: Learning-based infrared small object detection methods currently rely heavily on the classification backbone network. This tends to result in tiny object loss and feature distinguishability ...

Abstract: Capturing stationary aerial objects on unmanned surface vehicles (USVs) is challenging due to quasiperiodic and fast floating-base motions caused by wave-induced disturbances. It is hard to ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

CTx001, a gene therapy for geographic atrophy, received FDA Fast Track Designation, expediting its development and review process. The Opti-GAIN phase 1/2 trial will assess CTx001's safety, ...

SAM 3D Objects is a foundation model that reconstructs full 3D shape geometry, texture, and layout from a single image, excelling in real-world scenarios with occlusion and clutter by using ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

Dogs confront a series of giant objects in a funny compilation. 'It's horrible': 5 Pinellas County Sheriff's Office deputies fired, accused of harassing inmates Farm-state Republicans finally reach ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

The trio spent one snap last preseason together before Brown suffered a shoulder injury that would knock him out for most of the 2024 season. Then Rice went down with a season-ending knee injury in ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...